The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
Protalix BioTherapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and internationally. The company offers Elelyso for the treatment of Gaucher disease. Its product pipeline comprises PRX-102, a therapeutic protein candidate, which is in the last stage of clinical trials for the treatment of Fabry diseases; PRX-110, a proprietary plant cell recombinant form of human deoxyribonuclease I that has completed phase IIa clinical trials for the treatment of cystic fibrosis; PRX-115, a plant cell-expressed recombinant PEGylated Uricase for the treatment of gout; and PRX-119, a plant cell-expressed PEGylated recombinant human DNase I product candidate for the treatment of NETs-related diseases. The company has agreements and partnerships with Pfizer; Fundação Oswaldo Cruz (Fiocruz); and Chiesi Farmaceutici S.p.A. The company was founded in 1993 and is based in Hackensack, New Jersey.
A 3-star rating suggests average performance compared to other similar companies.
The economic moat refers to the competitive advantage a company has over its competitors. A narrow moat suggests that the company has a less sustainable competitive advantage compared to those with wider moats.
This ratio indicates whether the stock is trading above (greater than 1) or below (less than 1) its fair value as determined by Morningstar's quantitative analysis. A ratio of 0.94 suggests the stock is currently trading at a slight discount (undervalued).
Extreme uncertainty in fair value estimates indicates exceptional potential volatility in the stock price. Investors should exercise caution and carefully assess their risk tolerance and investment strategy when considering stocks with this level of uncertainty.
These price estimates indicate the price levels at which Morningstar would consider the stock significantly overvalued (one-star) or undervalued (five-star) based on their analysis.
Moderate financial health suggests stability but also indicates potential risks. Evaluate the company's ability to manage its financial obligations and fund growth initiatives.
Valuation vs. Price: The stock is currently considered undervalued relative to its fair value, which could present a buying opportunity if you believe in Morningstar's valuation methodology.
Moat and Competitive Position: The narrow economic moat indicates less sustainable competitive advantages. Consider whether the company's business model and market position align with your investment goals.
Financial Health: Moderate financial health suggests stability but also indicates potential risks. Evaluate the company's ability to manage its financial obligations and fund growth initiatives.
Uncertainty: High uncertainty in fair value estimates implies potential volatility in the stock price. Factor in your risk tolerance and investment horizon when assessing this uncertainty.
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
Event will take place on Wednesday, June 26, 2024 in New York CARMIEL, Israel , June 13, 2024 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX), a biopharmaceutical company focused ...
PHILADELPHIA, PA / ACCESSWIRE / June 11, 2024 / Kaskela Law LLC announces that it is investigating Protalix BioTherapeutics, Inc. (NYSE:PLX) ("Protalix") on behalf of the company's shareholders. Since...
Corporate presentation scheduled for Monday, June 3, 2024 at 2:30 P.M. PDT CARMIEL, Israel , May 29, 2024 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX), a biopharmaceutical com...
PROTALIX BIOTHERAPEUTICS C O R P O R A T E P R E S E N T A T I O N M a y 2 0 2 4 Disclaimers Third-Party Information This presentation also contains estimates and other data made by independent partie...
Company to host conference call and webcast today at 8:30 a.m. EDT CARMIEL, Israel , May 10, 2024 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX), a biopharmaceutical company focu...
Protalix BioTherapeutics, Inc. (PLX) Q4 2023 Earnings Call Transcript...
Company to host conference call and webcast today at 8:30 a.m. EDT CARMIEL, Israel , March 14, 2024 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX), a biopharmaceutical company fo...
Corporate presentation scheduled for Monday, February 26, 2024 at 1:00 PM ET CARMIEL, Israel , Feb. 23, 2024 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX), a biopharmaceutical ...
CARMIEL, Israel , Dec. 26, 2023 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombi...